Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02752685
Title Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors New York University School of Medicine
Indications

Her2-receptor negative breast cancer

triple-receptor negative breast cancer

Therapies

Nab-paclitaxel + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.